Form 4 for MRNA Moderna
Accepted 2026-09-16 16:48:33 ET · period of report 2026-09-14 · accession 0001682852-26-000176 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-16 16:48 | 2026-09-14+ | MRNA | Hoge Stephen | Pres | M - OptEx | $12.21 | +152.9K | 1.60M | +11% | +$1.87M |
| DMT | 2026-09-16 16:48 | 2026-09-14+ | MRNA | Hoge Stephen | Pres | S - Sale+OE | $145.10 | -80.6K | 1.56M | -5% | -$11.69M |
| DMT | 2026-09-16 16:48 | 2026-09-14+ | MRNA | Hoge Stephen | Pres | M - OptEx | $0.00 | -152.9K | 305.8K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-14 | M | A | 76,453 | $12.21 | 1,566,152 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. |
| 2 | Common | Common Stock | 2026-09-14 | S | D | 40,294 | $144.13 | 1,525,858 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 3 | Common | Common Stock | 2026-09-15 | M | A | 76,452 | $12.21 | 1,602,310 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. |
| 4 | Common | Common Stock | 2026-09-15 | S | D | 40,281 | $146.07 | 1,562,029 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-09-14 | M | D | 76,453 | $0.00 | 382,262 | D | $12.21 · — to 2027-02-23 | 76,453 Common Stock | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. (F5) This option is fully vested and exercisable. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-09-15 | M | D | 76,452 | $0.00 | 305,810 | D | $12.21 · — to 2027-02-23 | 76,452 Common Stock | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. (F5) This option is fully vested and exercisable. |